Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2017 September;42(3) > Minerva Endocrinologica 2017 September;42(3):280-9



To subscribe PROMO
Submit an article
Recommend to your librarian


Publication history
Cite this article as



Minerva Endocrinologica 2017 September;42(3):280-9

DOI: 10.23736/S0391-1977.16.02232-X


language: English

Emergence of SFRP5 as a pleiotropic adipocytokine and its association with Wnt signaling pathways

Chandrasekaran JAIKANTH 1, Prema GURUMURTHY 1 , Thillai INDHUMATHI 2, Kotturathu M., CHERIAN 3

1 Department of Biochemical Pharmacology, Frontier Lifeline Hospital, Chennai, India; 2 Medical Officer, Take Care Hospital, Chennai, India; 3 Department of Cardiology, Frontier Lifeline Hospital, Chennai, India


The widespread perception of obesity as a non-communicable disease is slowly giving way to the view of a contagious, communicable and potentially fatal condition. The downstream comorbidities associated with it are endless. Hence, the slogan “Fat To Fit” is being promoted worldwide. The view of white adipose tissue as a fat storage organ is now shifting to an endocrine organ. The secreted hormones, called adipocytokines, act in an autocrine, paracrine, and endocrine fashion. Like other hormones, they can have a positive as well as a negative influence over the body. Secreted frizzled-related protein 5 (SFRP5) is a recently identified novel adipocytokine which falls under the category of those adipokines which have a positive influence on the system. Plasma SFRP5 levels are significantly lower in patients with obesity, insulin resistance and diabetes, a condition which contributes to the major components of the metabolic syndrome and to other disease conditions like atherosclerosis, autoimmune disorders, etc. This review article focuses on the effects of SFRP5 on the major systems of the body and on its association with the Wnt signaling pathways.

KEY WORDS: SFRP5 protein, human - Adipocytokines - Fat mass and obesity-associated protein, human - Metabolic diseases - Wnt signaling pathway

top of page